1
2
3
4
5
VMT, in the US referred to as symptomatic VMA (vitreo macular adhesion), is an age-related
progressive, sight-threatening condition that may lead to visual
distortion, decreased visual acuity and central blindness. It is
estimated that 250,000 to 300,000 patients in Europe alone suffer from
this condition.
JETREA®, a recombinant form of a human protein (plasmin), is administered through a one-time, single intravitreal injection. It targets the protein fibers which cause the abnormal pulling between vitreous and macula that cause VMT. By dissolving these proteins, JETREA®releases the traction, and helps to complete the detachment of the vitreous from the macula.